4Q Financial Reports: Genentech

Genentech

4Q Revenues: $1.9 billion (+44%)

4Q Earnings: $339.2 million (+64%)

FY Revenues: $6.6 billion (+44%)

FY Earnings: $1.3 billion (+63%)

Comments: Product sales were up 45% in 2005 to $5.2 million. Sales for the quarter increased 47% to $1.5 million. Rituxan sales were up 16% for the year to $1.8 million and sales for the quarter were up 13% to $484.4 million. Sales of Avastin increased 108% for the year to $1.1 billion and sales increased 89% to $359.1 million for the quarter. Herceptin sales increased 56% for the year to $747.2 million and 98% to $250.1 million for the quarter. Tarceva sales were $274.9 million for the year, compared to $13.3 million in 2004. Xolair sales increased 71% to $320.6 million for the year and increased 55% to $93.3 million for the quarter.